A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters
Discover our longstanding love for gardening and how it started with Schatzi’s chives.
Search
Recognizing Parents Supporting Other Parents
Recognizing Parents Supporting Other Parents
Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire
Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire
Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Clinical Development and Operations
Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim and Vanderbilt University join forces
Leadership insights about our focus on patient centricity
Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement
Simon Manyara
Simon Manhara works with our culture and sustainability team towards making a positive social impact and creating a sustainable future.
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.
Patricia Rangel | Boehringer Ingelheim Careers
"Patricia Rangel of Corporate Strategy & Consulting describes Boehringer Ingelheim as a family company that operates with the highest integrity standards."
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Federal and State Laws
Federal and State Laws
Alex Breiner
Alexandra Breiner, a Senior Communications Manager in Corporate Affairs, highlights her career and the many development programmes at Boehringer Ingelheim.
Shannon Rountos
Shannon Rountos, Head of Newsroom within Corporate Affairs, speaks about her rewarding and fulfilling career in Boehringer Ingelheim.
Stefanie Bock Kreilinger
Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Press Material
Find the latest press releases from Boehringer Ingelheim on animal health or access our media pool to view BI corporate news.
Cristian Torreblanca
Cristian Torreblanca Estrada, a Corporate GFE Senior Manager Controller in Germany talks about opportunities to move between professional areas and countries
Flying animals to safety with Greater Good Charities
Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.
Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation
Confronting health disparities in clinical trials
As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.
Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes
Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes
When Passion Starts as a Family Value and Continues as a Work Value
Discover who inspires members of our LatinX Business Resource Group.